New drug combo shows promise for Hard-to-Treat cancers
NCT ID NCT07414836
First seen Feb 21, 2026 · Last updated May 07, 2026 · Updated 12 times
Summary
This early-phase study tests a new drug called BG-C0979, alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. About 84 adults with various advanced cancers will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Icon Cancer Centre South Brisbane
RECRUITINGSouth Brisbane, Queensland, QLD 4101, Australia
-
Next Oncology San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
-
Northern Beaches Hospital
RECRUITINGFrenchs Forest, New South Wales, NSW 2086, Australia
Conditions
Explore the condition pages connected to this study.